BioAdvance News

This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

By WebmasterFebruary 24, 2020November 1st, 2024No Comments

This isn’t a ‘biotech bubble,’ it’s ‘Philadelphia’s moment’ to become a center for gene therapy, says Penn-based CEO

Previous PostAnnovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
Next PostAnne Prener, M.D., Ph.D. Appointed to Renovacor Board of Directors and Scientific Advisory Board